Abstract
Over the last century, the prevalence of type 2 diabetes has dramatically increased, reaching the status of epidemic. Because insulin resistance is considered the primary cause of type 2 diabetes, the identification of the cellular processes and gene networks that lead to an impairment of insulin action in target tissues is of crucial importance for the development of new drugs and therapeutic strategies to treat or prevent the disease. Numerous studies in humans and animal models have shown that insulin resistance is frequently associated to reduced mitochondrial mass or oxidative function in insulin sensitive tissues, leading to the hypothesis that defective overall mitochondrial activity could play a relevant role in the etiology of insulin resistance and, therefore, in type 2 diabetes. Although the causal relationship between mitochondrial dysfunction and insulin resistance is still controversial, numerous studies show that lifestyle or pharmacological interventions that improve insulin sensitivity are frequently associated to an increase in mitochondrial function and whole body energy expenditure. Therefore, increasing mitochondrial mass and oxidative activity is viewed as a potential therapeutic approach for the treatment of insulin resistance. Here, we review the current knowledge on the role of mitochondria in the pathogenesis of insulin resistance and discuss some of the potential therapeutic strategies and pharmacological targets for the treatment of insulin resistance based on the activation of mitochondrial biogenesis and the increase of mitochondrial oxidative function.
Keywords: Type 2 diabetes, mitochondrial dysfunction, calorie restriction, exercise, AMPK, SIRT1, PGC-1.
Current Pharmaceutical Design
Title:Targeting Mitochondrial Biogenesis to Treat Insulin Resistance
Volume: 20 Issue: 35
Author(s): Monica Zamora and Josep A. Villena
Affiliation:
Keywords: Type 2 diabetes, mitochondrial dysfunction, calorie restriction, exercise, AMPK, SIRT1, PGC-1.
Abstract: Over the last century, the prevalence of type 2 diabetes has dramatically increased, reaching the status of epidemic. Because insulin resistance is considered the primary cause of type 2 diabetes, the identification of the cellular processes and gene networks that lead to an impairment of insulin action in target tissues is of crucial importance for the development of new drugs and therapeutic strategies to treat or prevent the disease. Numerous studies in humans and animal models have shown that insulin resistance is frequently associated to reduced mitochondrial mass or oxidative function in insulin sensitive tissues, leading to the hypothesis that defective overall mitochondrial activity could play a relevant role in the etiology of insulin resistance and, therefore, in type 2 diabetes. Although the causal relationship between mitochondrial dysfunction and insulin resistance is still controversial, numerous studies show that lifestyle or pharmacological interventions that improve insulin sensitivity are frequently associated to an increase in mitochondrial function and whole body energy expenditure. Therefore, increasing mitochondrial mass and oxidative activity is viewed as a potential therapeutic approach for the treatment of insulin resistance. Here, we review the current knowledge on the role of mitochondria in the pathogenesis of insulin resistance and discuss some of the potential therapeutic strategies and pharmacological targets for the treatment of insulin resistance based on the activation of mitochondrial biogenesis and the increase of mitochondrial oxidative function.
Export Options
About this article
Cite this article as:
Zamora Monica and Villena A. Josep, Targeting Mitochondrial Biogenesis to Treat Insulin Resistance, Current Pharmaceutical Design 2014; 20 (35) . https://dx.doi.org/10.2174/1381612820666140306102514
DOI https://dx.doi.org/10.2174/1381612820666140306102514 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Glycosaminoglycan Sulodexide Inhibition of MMP-9 Gelatinase Secretion and Activity: Possible Pharmacological Role Against Collagen Degradation in Vascular Chronic Diseases
Current Vascular Pharmacology Herbs for Effective Treatment of Diabetes Mellitus Wounds: Medicinal Chemistry and Future Therapeutic Options
Mini-Reviews in Medicinal Chemistry Pleiotropic Effects of Fenofibrate
Current Pharmaceutical Design A New Biomarker with High Outcome Prediction in IgA Nephropathy
Recent Patents on Biomarkers Is Combined Angiotensin-converting Enzyme Inhibition and Angiotensin Receptor Blockade Associated with Increased Risk of Cardiovascular Death in Hemodialysis Patients?
Current Hypertension Reviews Catastrophic Antiphospholipid Syndrome - 20 Years Later
Current Rheumatology Reviews Diabetic Nephropathy: Causes and Managements
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Natriuretic Peptide Family: New Aspects
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Matrix Metalloproteinases and their Tissue Inhibitors in Diabetes, Atherosclerosis and Prediction of the Cardiovascular Risk
Current Enzyme Inhibition Editorial [ Diseases of the Kidney: Molecular Mechanisms and Current Therapy Executive Editor: Stephen I-Hong Hsu ]
Current Molecular Medicine In Silico Validation for the Modulatory Effect of Tea Catechins on Erythrocyte Na<sup>+</sup>/K<sup>+</sup>-ATPase
The Natural Products Journal Atherosclerotic Renal Artery Stenosis: An Update on Diagnosis and Management
Current Vascular Pharmacology Membrane Permeable Lipophilic Cations as Mitochondrial Directing Groups
Current Topics in Medicinal Chemistry A New Protocol of Type 2 Diabetes Induction and Hydrocortisone Effects on Beta-Cells Signaling in Mice
Current Chemical Biology Evaluation of Intermediate Endpoints: Clinical Implications in the Management of Arterial Hypertension
Current Hypertension Reviews Bioartificial Pancreas: Drug Delivery through Islet Microencapsulation to Treat Diabetes
Recent Patents on Biomedical Engineering (Discontinued) Wound-Associated Skin Fibrosis: Mechanisms and Treatments Based on Modulating the Inflammatory Response
Endocrine, Metabolic & Immune Disorders - Drug Targets Renal Microcirculation and Calcium Channel Subtypes
Current Hypertension Reviews Acute Renal Failure in Different Malignant Tumors
Current Medicinal Chemistry Fighting Alzheimer's Disease and Type 2 Diabetes: Pathological links and Treatment Strategies
CNS & Neurological Disorders - Drug Targets